Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276 | Completed Phase 2 Results FDA Drug

• 2 other identifiers: QHD00028U1111-1266-7472
• Study Type: interventional
• Target: 306
• Locations: 1 country
• Sites: 6

Brief Summary

The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine administered concomitantly or singly in adults 65 years of age and older having received their second dose of the 2-dose schedule of Moderna COVID-19 vaccine at least 5 months before enrollment in the study.

Conditions

Influenza Immunization; Healthy Volunteers

Outcome Measures

Primary Outcomes (18)

• Number of Participants With Immediate Unsolicited Adverse Events (AEs)

  An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs in the CRF. Reported AEs for each arm were presented as pre-specified in the study protocol.

  Within 30 minutes post vaccination

• Number of Participants With Solicited Injection Site Reactions

  A solicited reaction (SR) was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited injection site reactions included injection site pain, axillary swelling and tenderness, injection site erythema, injection site swelling, injection site induration, and injection site bruising. Reported AEs for each arm were presented as pre-specified in the study protocol.

  Within 7 days post-vaccination

• Number of Participants With Solicited Systemic Reactions

  A SR was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia, shivering, fatigue, nausea and vomiting. Reported AEs for each arm were presented as pre-specified in the study protocol.

  Within 7 days post-vaccination

• Number of Participants With Unsolicited Adverse Events

  An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.

  Within 21 days post-vaccination

• Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)

  An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs was defined as one of scientific and medical concern specific to the sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was done. Reported AEs for each arm were presented as pre-specified in the study protocol.

  From Day 1 up to 6 months post-vaccination

• Number of Participants With Medically Attended Adverse Events (MAAEs)

  A MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department including medical advice seeking during the study visit or routine medical care. Reported AEs for each arm were presented as pre-specified in the study protocol.

  From Day 1 up to 6 months post-vaccination

• Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 1

  GMTs of anti-influenza and anti-COVID-19 antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.

  Day 1 (pre-vaccination)

• Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 22

  GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.

  Day 22 (post-vaccination)

• Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine and COVID-19 Vaccine Antibodies

  GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMTRs were calculated as the ratio of GMTs post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.

  Day 1 (pre-vaccination) and Day 22 (post-vaccination)

• Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

  Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.

  Day 1 (pre-vaccination)

• Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

  Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.

  Day 22 (post-vaccination)

• Percentage of Participants Achieving Seroconversion Against Influenza and COVID-19 Virus Antigens

  Anti-influenza and anti-COVID-19 antibodies were measured by HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer less than (\<)10 (1/dilution) and a post-vaccination titer \>=40 (1/dilution) or a pre-vaccination titer \>=10 (1/dilution) and a \>= four-fold increase in post-vaccination titer at Day 22.

  Day 22 (post-vaccination)

• Percentage of Participants With Antibody Titers >=40 (1/Dilution)

  Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.

  Day 1 (pre-vaccination)

• Percentage of Participants With Antibody Titers >=40 (1/Dilution)

  Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.

  Day 22 (post-vaccination)

• Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies

  GMCs of Anti-S binding IgG antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) method and were measured in binding antibody units/milliliter (BAU/mL).

  Day 1 (pre-vaccination)

• Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies

  GMCs of Anti-S binding IgG antibodies were assessed using ELISA method and were measured in BAU/mL.

  Day 22 (post-vaccination)

• Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies

  GMCs of Anti-S binding IgG antibodies were assessed using ELISA method. GMCR was calculated as the ratio of GMC post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.

  Day 1 (pre-vaccination) and Day 22 (post-vaccination)

• Percentage of Participants With >=2-Fold and >=4-Fold Rise in Anti-S Binding IgG Antibodies

  Percentage of participants with \>=2-fold and \>=4-fold rise in Anti-S binding IgG antibodies at Day 22 (post-vaccination) are reported in this outcome measure. Percentage of participants with \>=2-fold rise are those for whom the computed value at Day 22 was \*2 compared to the computed value at Day 1 and percentage of participants with \>=4-fold rise are those for whom the computed value at Day 22 was \*4 compared to the computed value at Day 1.

  Day 22 (post-vaccination)

Study Arms (3)

Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine

EXPERIMENTAL

Participants received an injection of 0.7 milliliters (mL), fluzone HD quadrivalent influenza vaccine, co-administered with 0.5 mL COVID-19 vaccine, intramuscularly (IM) on Day 1.

Biological: Quadrivalent Inactivated Influenza High Dose; Biological: COVID-19 mRNA Vaccine (nucleoside modified)

Group 2: Fluzone HD Quadrivalent Influenza Vaccine

ACTIVE COMPARATOR

Participants received a single injection of 0.7 mL fluzone HD quadrivalent influenza vaccine, IM on Day 1.

Biological: Quadrivalent Inactivated Influenza High Dose

Group 3: COVID-19 Vaccine

ACTIVE COMPARATOR

Participants received a single injection of 0.5 mL COVID-19 mRNA Vaccine, IM on Day 1.

Biological: COVID-19 mRNA Vaccine (nucleoside modified)

Interventions

Quadrivalent Inactivated Influenza High Dose BIOLOGICAL

Sterile suspension for injection in a pre-filled syringe Intramuscular injection

Also known as: Fluzone HD Quadrivalent vaccine

Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine; Group 2: Fluzone HD Quadrivalent Influenza Vaccine

COVID-19 mRNA Vaccine (nucleoside modified) BIOLOGICAL

Sterile suspension (white to off-white) in multidose vial Intramuscular injection

Also known as: Moderna COVID-19 Vaccine (mRNA-1273 vaccine)

Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine; Group 3: COVID-19 Vaccine

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)

You may qualify if:

• In good health or with underlying medical condition(s) that were judged to be stable by the Investigator. A stable medical condition was defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
• Participants who previously received 2 injections of Moderna COVID-19 Vaccine with the second dose received at least 5 months before Visit 1.
• Abled to attend all scheduled visits and to complied with all study procedures.

You may not qualify if:

• Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances.
• Previous dermal filler injection (either lips or face fillers).
• Thrombocytopenia, contraindicated IM injection.
• Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with study conduct or completion.
• Moderate or severe acute illness/infection (according to Investigator judgment) on the day of study intervention administration or febrile illness (temperature \>= 100.4°Fahrenheit \[F\] \[38.0° Celsius {C}\]). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.
• History of serious adverse reaction to any influenza or COVID-19 vaccines.
• Personal history of Guillain-Barré syndrome (GBS).
• Personal history of clinically significant developmental delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder.
• Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C.
• Any condition that in the opinion of the Investigator posed a health risk to the participant if enrolled or could interfere with the evaluation of the vaccine.
• Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
• Participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating vaccine, drug, medical device, or medical procedure.
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
• Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
• The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Sponsors & Collaborators

• Sanofi Pasteur, a Sanofi Company: lead

Study Sites (6)

Investigational Site Number :8400003

Glendale, Arizona, 85306, United States

Location

Investigational Site Number :8400006

San Diego, California, 92108, United States

Location

Investigational Site Number :8400004

Vista, California, 92083, United States

Location

Investigational Site Number :8400005

Centennial, Colorado, 80112, United States

Location

Investigational Site Number :8400001

Peoria, Illinois, 61614, United States

Location

Investigational Site Number :8400002

Austin, Texas, 78705, United States

Location

Related Publications (1)

• Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, Pandey A, Perez L, Sater N, Shrestha A, Wague S, Samson SI. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged >/=65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022 Apr;10(4):392-402. doi: 10.1016/S2213-2600(21)00557-9. Epub 2022 Feb 1.

  PMID: 35114141 DERIVED

Related Links

• QHD00028 Plain Language Results Summary

MeSH Terms

Conditions

Influenza, Human

Interventions

CVnCoV COVID-19 vaccine; 2019-nCoV Vaccine mRNA-1273

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

mRNA Vaccines; Nucleic Acid-Based Vaccines; Vaccines, Synthetic; Recombinant Proteins; Proteins; Amino Acids, Peptides, and Proteins; Vaccines; Biological Products; Complex Mixtures; COVID-19 Vaccines; Viral Vaccines; Antigens; Biological Factors

Results Point of Contact

• Title: Trial Transparency Team
• Organization: Sanofi Pasteur

Contact-US@sanofi.com

800-633-1610

Study Officials

• Clinical Sciences & Operations

  Sanofi

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 16, 2021
• First Posted: July 20, 2021
• Study Start: July 16, 2021
• Primary Completion: February 8, 2022
• Study Completion: February 8, 2022
• Last Updated: September 12, 2025
• Results First Posted: December 13, 2022

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

US (6)